Patient dosing has begun in Cyclerion Therapeutic’s Phase 2a trial testing CY6463, a disease-modifying therapy for people with Alzheimer’s disease who have cardiovascular risk factors — health conditions that increase the risk of heart disease. The experimental oral therapy is designed to improve cognition and function in people with Alzheimer’s. “We believe that CY6463 has potential to provide meaningful cognitive benefits and are very pleased to have initiated this important clinical study,” Andreas Busch, PhD, chief…
You must be logged in to read/download the full post.
The post Dosing Begins in Trial of CY6463 for Patients With Cardiovascular Risk appeared first on BioNewsFeeds.